Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004405813 | SCV004888502 | uncertain significance | Inborn genetic diseases | 2023-12-12 | criteria provided, single submitter | clinical testing | The c.1819C>T (p.R607W) alteration is located in exon 15 (coding exon 15) of the ALG9 gene. This alteration results from a C to T substitution at nucleotide position 1819, causing the arginine (R) at amino acid position 607 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005040650 | SCV005680963 | uncertain significance | ALG9 congenital disorder of glycosylation; Gillessen-Kaesbach-Nishimura syndrome | 2023-12-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005104483 | SCV005803739 | uncertain significance | ALG9 congenital disorder of glycosylation | 2024-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 607 of the ALG9 protein (p.Arg607Trp). This variant is present in population databases (rs781849410, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with ALG9-related conditions. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |